India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the quarter ended September 30, 2020, which is the second quarter of its
2021 fiscal year, and the start of Phase 1 cannabinoid-based clinical trial for Alzheimer’s Patients.

Revenue in the quarter ended September 30, 2020 and September 30, 2019, were $125 thousand